Trial reportDiabetes2011
C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.
Trial report in Diabetes, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 46 citations in OpenAlex.
- Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.Diabetes · 2013Trial
- Latest Updates in Prevention and Screening of Type 1 Diabetes Mellitus.Current pediatrics reports · 2025Article
- Immunotherapies for prevention and treatment of type 1 diabetes.Immunotherapy · 2025Review
- Immunotherapy for Type 1 Diabetes: Mechanistic Insights and Impact of Delivery Systems.Current pharmaceutical design · 2025Review
- Study of Water- and Organic-Soluble Extracts fromJournal of diabetes research · 2022Article
- Immune Checkpoint-Bioengineered Beta Cell Vaccine Reverses Early-Onset Type 1 Diabetes.Advanced materials (Deerfield Beach, Fla.) · 2021Article
- Topical steroid therapy induces pro-tolerogenic changes in Langerhans cells in human skin.Immunology · 2015Article
- The CXCR1/2 Pathway: Involvement in Diabetes Pathophysiology and Potential Target for T1D Interventions.Current diabetes reports · 2015Review
- Combination immunotherapies for type 1 diabetes mellitus.Nature reviews. Endocrinology · 2015Review
- Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review.Clinical reviews in allergy & immunology · 2014Review
- Immune modulation in humans: implications for type 1 diabetes mellitus.Nature reviews. Endocrinology · 2014Review
- Type 1 diabetes.Lancet (London, England) · 2014Review
- Trials in type 1 diabetes: Antigen-specific therapies.Clinical immunology (Orlando, Fla.) · 2013Review
- Progress in immune-based therapies for type 1 diabetes.Clinical and experimental immunology · 2013Review
- Treating human autoimmunity: current practice and future prospects.Science translational medicine · 2012Review
- Dead or alive?Diabetes care · 2012Article
- Clinical potential of antigen-specific therapies in type 1 diabetes.The review of diabetic studies : RDS · 2012Review
- Type 1 diabetes mellitus in 2011: Heterogeneity of T1DM raises questions for therapy.Nature reviews. Endocrinology · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate whether lower risk HLA class II genotypes would influence the efficacy of DiaPep277 therapy in protecting β-cell function evaluated by C-peptide secretion in recent-onset type 1 diabetic subjects. RESEARCH DESIGN AND
methodsData were collected from type 1 diabetic subjects enrolled in multicenter phase II studies with a randomized, double-blind, and placebo-controlled design in whom fasting and stimulated C-peptide levels were measured. HLA genotypes were classified in high, moderate, and low risk categories.
resultsA total of 146 subjects (aged 4.3 to 58.5 years) were enrolled, including 76 children (<18 years old) and 70 adults. At baseline, there was a significant increase in fasting, maximal, and area under the curve (AUC) C-peptide from high to moderate and low risk HLA genotypes in adults (P for trend <0.04) but not in children. Children showed a decrease of the three parameters over time regardless of therapy and HLA genotype. DiaPep277-treated adults with low risk genotype had significantly higher maximal and AUC C-peptide versus placebo at 12 months (0.04 ± 0.07 vs. -0.28 ± 0.09 nmol/L, P < 0.01, and 0.53 ± 1.3 vs. -4.59 ± 1.5 nmol/L, P < 0.05, respectively). In the moderate risk genotype group, Δmaximal and AUC C-peptide values were significantly higher in DiaPep277-treated versus placebo-treated patients (P < 0.01 and P < 0.05, respectively).
conclusionsThis exploratory study demonstrates that type 1 diabetic adults with low and moderate risk HLA genotypes benefit the most from intervention with DiaPep277; the only subgroup with an increase of C-peptide at 12 months after diagnosis was the low risk DiaPep277-treated subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.